Table 1.
Summary of Clinical and Pathologic Features.
| Feature | Number of Patients | % of Patients |
| Sex | ||
| Male | 348 | 62 |
| Female | 212 | 38 |
| Age at surgery (median, 63 years; range, 25–89 years) | ||
| <65 years | 310 | 55 |
| ≥65 years | 250 | 45 |
| Karnofsky performance status scale | ||
| ≥80% | 512 | 91 |
| <80% | 48 | 9 |
| Tumor extent (TNM 2002) | ||
| pT1 | 304 | 54 |
| pT2 | 59 | 11 |
| pT3 | 186 | 33 |
| pT4 | 11 | 2 |
| Regional lymph node metastasis (TNM 2002) | ||
| N0/pN0 | 519 | 93 |
| pN1, pN2 | 41 | 7 |
| Distant metastasis (TNM 2002) | ||
| Yes | 87 | 16 |
| No | 473 | 84 |
| Grade of malignancy* | ||
| G1 | 146 | 26 |
| G2 | 321 | 58 |
| G3 | 87 | 16 |
| G4 | 3 | <1 |
| Histopathologic subtype | ||
| Clear-cell (conventional) RCC | 464 | 83 |
| Papillary (chromophil) RCC | 48 | 9 |
| Chromophobe RCC | 25 | 4 |
| Spindle cell carcinoma | 5 | <1 |
| Collecting duct carcinoma | 2 | <1 |
| Unclassified RCC | 16 | 3 |
| Type of surgery | ||
| Partial nephrectomy | 81 | 14 |
| Radical nephrectomy | 479 | 86 |
| Treatment for metastasized disease† | ||
| Yes | 25 | 29 |
| No | 62 | 71 |
*
Three patients with tumors of unknown grade.
†
Interferon-alpha. and IL-2.based immunotherapy.